Work

Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin

Year: 2018

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2018.07.064

Authors: Jonathan Kolitz, Stephen A. Strickland, Jorge E. Cortes, Donna Hogge, Jeffrey E. Lancet, Stuart Goldberg, Robert J. Ryan, Michael Chiarella, Arthur C. Louie, Geoffrey L. Uy

Institutions: Northwell Health, Vanderbilt University, Vanderbilt-Ingram Cancer Center, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Hackensack University Medical Center, Jazz Pharmaceuticals (United States), Washington University in St. Louis

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889152482

FWCI: 0.537

Cites:

Cited by: 4

Related to: 10